Literature DB >> 12915070

Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease.

Robert Y Moore1.   

Abstract

Understanding of the pathophysiology of Parkinson disease (PD) has advanced rapidly over the last two decades through basic and clinical studies using modern neuroanatomical, clinical assessment, neuropathological and functional brain imaging methods. Two interacting processes determine the development of functional impairment, neuronal degeneration with selective denervation of specific regions and compensatory responses, which oppose the effects of denervation. The clinical manifestations of PD, at least in early stages, reflect selective degeneration of dopamine neurons in the substantia nigra projecting through the nigrostriatal pathway to the caudal putamen with compensatory changes in this and related systems. Positron emission tomography with specific ligands for the dopamine system is a powerful tool for analysis of both degenerative and compensatory processes in the pathophysiology of Parkinson disease in vivo and can be used to confirm the diagnosis of dopamine deficient Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915070     DOI: 10.1016/s1353-8020(03)00063-4

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  13 in total

1.  Neural correlates of the core facets of empathy in schizophrenia.

Authors:  Birgit Derntl; Andreas Finkelmeyer; Bianca Voss; Simon B Eickhoff; Thilo Kellermann; Frank Schneider; Ute Habel
Journal:  Schizophr Res       Date:  2012-02-04       Impact factor: 4.939

2.  Transcription and epigenetic profile of the promoter, first exon and first intron of the human tyrosine hydroxylase gene.

Authors:  Gaetano Romano; Marcella Macaluso; Chiara Lucchetti; Lorraine Iacovitti
Journal:  J Cell Physiol       Date:  2007-05       Impact factor: 6.384

3.  Tyrosine hydroxylase gene regulation in human neuronal progenitor cells does not depend on Nurr1 as in the murine and rat systems.

Authors:  Hao Jin; Gaetano Romano; Cheryl Marshall; Angela E Donaldson; Sokreine Suon; Lorraine Iacovitti
Journal:  J Cell Physiol       Date:  2006-04       Impact factor: 6.384

Review 4.  Nanomedicine in Central Nervous System (CNS) Disorders: A Present and Future Prospective.

Authors:  Shringika Soni; Rakesh Kumar Ruhela; Bikash Medhi
Journal:  Adv Pharm Bull       Date:  2016-09-25

5.  Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease.

Authors:  James A Olzmann; Jill R Bordelon; E Chris Muly; Howard D Rees; Allan I Levey; Lian Li; Lih-Shen Chin
Journal:  J Comp Neurol       Date:  2007-01-20       Impact factor: 3.215

6.  Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.

Authors:  Janet Cunningham; Philip Pivirotto; John Bringas; Brian Suzuki; Sharmila Vijay; Laura Sanftner; Marina Kitamura; Curtis Chan; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2008-06-03       Impact factor: 11.454

7.  Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.

Authors:  Aurelija Jucaite; Ikuo Odano; Hans Olsson; Stefan Pauli; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-03       Impact factor: 9.236

8.  Conditioning Against the Pathology of Parkinson's disease.

Authors:  Rehana K Leak
Journal:  Cond Med       Date:  2018-04-28

9.  Parkinson's Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach.

Authors:  Alexandra Sofia Rua Rafael; Joselina Maria Pinto Barbosa; Maria José Silva Leão Rosas; Maria Carolina Lobo Almeida Garrett
Journal:  Porto Biomed J       Date:  2016-09-17

10.  Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder.

Authors:  Garrett E Alexander
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.